



# TGF $\beta$ -Induced Deptor Suppression Recruits mTORC1 and Not mTORC2 to Enhance Collagen I ( $\alpha$ 2) Gene Expression

Falguni Das<sup>1</sup>, Amit Bera<sup>1</sup>, Nandini Ghosh-Choudhury<sup>2,4</sup>, Hanna E. Abboud<sup>1,4</sup>, Balakuntalam S. Kasinath<sup>1,4</sup>, Goutam Ghosh Choudhury<sup>1,3,4\*</sup>

**1** Departments of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America, **2** Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America, **3** Geriatric Research, Education and Clinical Center, South Texas Veterans Health Care System, San Antonio, Texas, United States of America, **4** VA Research, South Texas Veterans Health Care System, San Antonio, Texas, United States of America

## Abstract

Enhanced TGF $\beta$  activity contributes to the accumulation of matrix proteins including collagen I ( $\alpha$ 2) by proximal tubular epithelial cells in progressive kidney disease. Although TGF $\beta$  rapidly activates its canonical Smad signaling pathway, it also recruits noncanonical pathway involving mTOR kinase to regulate renal matrix expansion. The mechanism by which chronic TGF $\beta$  treatment maintains increased mTOR activity to induce the matrix protein collagen I ( $\alpha$ 2) expression is not known. Deptor is an mTOR interacting protein that suppresses mTOR activity in both mTORC1 and mTORC2. In proximal tubular epithelial cells, TGF $\beta$  reduced deptor levels in a time-dependent manner with concomitant increase in both mTORC1 and mTORC2 activities. Expression of deptor abrogated activity of mTORC1 and mTORC2, resulting in inhibition of collagen I ( $\alpha$ 2) mRNA and protein expression via transcriptional mechanism. In contrast, neutralization of endogenous deptor by shRNAs increased activity of both mTOR complexes and expression of collagen I ( $\alpha$ 2) similar to TGF $\beta$  treatment. Importantly, downregulation of deptor by TGF $\beta$  increased the expression of Hif1 $\alpha$  by increasing translation of its mRNA. TGF $\beta$ -induced deptor downregulation promotes Hif1 $\alpha$  binding to its cognate hypoxia responsive element in the collagen I ( $\alpha$ 2) gene to control its protein expression via direct transcriptional mechanism. Interestingly, knockdown of raptor to specifically block mTORC1 activity significantly inhibited expression of collagen I ( $\alpha$ 2) and Hif1 $\alpha$  while inhibition of rictor to prevent selectively mTORC2 activation did not have any effect. Critically, our data provide evidence for the requirement of TGF $\beta$ -activated mTORC1 only by deptor downregulation, which dominates upon the bystander mTORC2 activity for enhanced expression of collagen I ( $\alpha$ 2). Our results also suggest the presence of a safeguard mechanism involving deptor-mediated suppression of mTORC1 activity against developing TGF $\beta$ -induced renal fibrosis.

**Citation:** Das F, Bera A, Ghosh-Choudhury N, Abboud HE, Kasinath BS, et al. (2014) TGF $\beta$ -Induced Deptor Suppression Recruits mTORC1 and Not mTORC2 to Enhance Collagen I ( $\alpha$ 2) Gene Expression. PLoS ONE 9(10): e109608. doi:10.1371/journal.pone.0109608

**Editor:** Soumitro Pal, Children's Hospital Boston & Harvard Medical School, United States of America

**Received:** June 10, 2014; **Accepted:** September 2, 2014; **Published:** October 15, 2014

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

**Data Availability:** The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.

**Funding:** This work was supported by National Institutes of Health RO1 DK50190 and Veterans Administration Research Service Merit Review 5I01BX000926 grants to GGC. GGC is a recipient of Veterans Administration Senior Research Career Scientist Award. HEA is supported by National Institutes of Health. NGC and BSK are supported by VA Merit Review grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* Email: choudhury@uthscsa.edu

## Introduction

Renal tubulointerstitial fibrosis represents the best predictor of clinical outcome of end-stage renal disease [1]. The initiation of phase of fibrosis involves infiltration of inflammatory cells that secrete profibrogenic growth factors and cytokines. One such factor, TGF $\beta$ , acts on various renal cells including the proximal tubular epithelial cells to increase expression of matrix proteins, which significantly contribute to the fibrotic process. TGF $\beta$  through binding to the type II receptor engages the FKBP12-bound type I receptor to induce heterotetramerization, increase in phosphorylation of type I receptor and release of FKBP12 [2,3]. Activated type I receptor then phosphorylates the receptor-specific Smads (Smad 3 and 2) at the C-terminus, which is then released from the type I receptor and SARA, a Smad-recruiting protein to the plasma membrane [4]. Subsequently, the receptor-specific Smads heterodimerize with co-Smad, Smad 4, and translocate to

the nucleus to bind to transcriptional coactivators or corepressors to regulate gene expression [5,6,7]. Although Smad 2 and 3 act downstream of TGF $\beta$  receptor function, a recent study indicated a protective function of Smad 2 in renal fibrosis and matrix protein expression in proximal tubular epithelial cells [8].

Apart from canonical Smad signaling, TGF $\beta$  has been shown to induce many kinase cascades that are known to be activated by receptor tyrosine kinases, such as Erk1/2, JNK1/2, p38 MAPK and c-Src tyrosine kinase [7,9,10]. Furthermore, TGF $\beta$  activates PI 3 kinase and Akt to regulate renal pathology including renal cell hypertrophy and fibrosis [11,12,13,14]. Recently, we and others have shown activation of mTOR kinase in response to TGF $\beta$  [15,16,17,18]. In mammals, mTOR exists in two distinct complexes mTORC1 and mTORC2, which differ in their compositions. Raptor is only present in mTORC1 while both rictor and Sin1 define mTORC2 [19,20,21]. The regulation of mTORC1 and mTORC2 catalytic activity is complex. For

example, raptor, the exclusive component of mTORC1, is phosphorylated by mTORC1 to increase its activity [22]. However, mTORC1 impairs activation of mTORC2 by phosphorylation of IRS-1 and Grb-2, which are involved in PI 3 kinase signaling [21,23,24]. On the other hand, mTORC2-mediated phosphorylation of Sin1 increases its stability by inhibiting its lysosomal degradation to maintain the mTORC2 activity [25]. In contrast to these results, a recent report established the mTORC1-activated S6 kinase-dependent inhibitory phosphorylation of Sin1 at Thr-86 and Thr-398, which are present in the N- and C-terminal domains necessary for interaction with rictor and mTOR, respectively [26]. The sensitivity of mTORC1 and mTORC2 to the macrolide rapamycin and substrate specificities differ significantly [20]. mTORC1 essentially regulates the anabolic program of the cells by controlling protein synthesis, mitochondrial biogenesis, lipogenesis and nucleotide biosynthesis [19,27]. On the other hand, mTORC2 controls cytoskeletal organization, cell survival, gluconeogenesis and lipogenesis by activating AGC kinases and inactivating class IIa histone deacetylases, respectively [20,21,28,29]. However, using rapamycin we and others have recently shown involvement of mTOR to contribute to renal cell pathology found in diabetic kidney disease including kidney hypertrophy and matrix protein expression [30,31,32,33,34]. More recently, we identified a role for both mTORC1 and mTORC2 in TGF $\beta$  induction of renal cell matrix protein synthesis [5,15,16,35]. The precise mechanism by which mTOR is activated to increase matrix protein expression is not known. Here we show that deptor, a recently identified negative regulatory component of both mTORC1 and mTORC2, contributes to TGF $\beta$ -induced matrix protein collagen I ( $\alpha$ 2) expression in human proximal tubular epithelial cells. We demonstrate that downregulation of deptor by TGF $\beta$  is necessary for collagen I ( $\alpha$ 2) expression. Furthermore, we show that deptor inhibits TGF $\beta$ -induced Hif1 $\alpha$ , which binds to the collagen I ( $\alpha$ 2) promoter to induce its transcription. We demonstrate that deptor regulates Hif1 $\alpha$  mRNA translation to increase its protein levels. Finally, we show that in type 2 diabetic mice, increased expression of TGF $\beta$  is associated with decreased deptor expression and enhanced Hif1 $\alpha$ , and collagen I ( $\alpha$ 2) levels. Thus our results demonstrate a significant role of deptor in regulating collagen I ( $\alpha$ 2) expression in TGF $\beta$ -mediated fibrotic response.

## Materials and Methods

### Materials

TGF $\beta$ 1 was purchased from R & D, Minneapolis, MN. NP-40, Na<sub>3</sub>VO<sub>4</sub>, phenylmethylsulfonyl fluoride, protease inhibitor cocktail, anti-FLAG (M5) and  $\beta$ -actin antibody were obtained from Sigma, St Louis, MO. Antibodies against phospho-S6 kinase (Thr-389), S6 kinase, phospho-4EBP-1 (Thr-37/46), 4EBP-1, phospho-Akt (Ser-473), phospho-Akt (Thr-308), phospho-tuberin (Thr-1462), phospho-PRAS40 (Thr-246), Akt, raptor, rictor and PRAS40 were purchased from Cell Signaling, Boston, MA. Antibodies against Hif1 $\alpha$ , deptor, tuberin and collagen I ( $\alpha$ 2) and siRNA against Hif1 $\alpha$  and scramble RNA were obtained from Santa Cruz Biotechnology, Delaware, CA. Detailed description of the antibodies is presented in Table S1. Tissue culture materials, cDNA synthesis kit and TRI reagent for RNA isolation, were obtained from Invitrogen, Carlsbad, CA. FuGENE HD transfection reagent and luciferase assay kit were purchased from Promega Inc. Madison, WI. RT<sup>2</sup> real-time SYBR green/ROX PCR mix and GAPDH primers were obtained from Qiagen. Luciferase assay kit was obtained from Promega. Plasmids containing FLAG-tagged deptor and deptor shRNAs (deptor sh1 and deptor sh2)

were constructed in the laboratory of Dr. David Sabatini, Whitehead Institute for Biomedical Research, Boston, MA and were obtained from Addgene. Vectors containing scramble RNA, raptor shRNA and rictor shRNA were used previously [16]. Hif1 $\alpha$  5' terminal oligopyrimidine tract (TOP)-Lux reporter plasmid was constructed in the laboratory of Dr. Charles Sawyers, University of California at Los Angeles and was obtained from John Blenis (Harvard Medical School) [36].

### Cell Culture and Treatment

The HK2 human kidney proximal tubular epithelial cells were grown in DMEM/F12 medium with 10% fetal bovine serum as described previously [37]. The mouse proximal tubular epithelial cells were grown in DMEM with low glucose in the presence of 7% fetal bovine serum [38]. The cells were starved in serum free medium for 24 hours and incubated with 2 ng/ml TGF $\beta$  for indicated periods of time.

### Cell Lysis and Immunoblotting

Incubated cells were washed twice with PBS and harvested in RIPA buffer (20 mM Tris-HCl, pH 7.5, 5 mM EDTA, 150 mM NaCl, 1% NP-40, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM PMSF and 0.1% protease cocktail). The cell monolayer was incubated at 4°C for 30 minutes before it was scraped and centrifuged at 4°C for 20 minutes. The supernatant was collected, protein estimated and equal amounts of protein were separated by SDS polyacrylamide gel electrophoresis. The separated proteins were transferred to PVDF membrane and immunoblotting was carried out using indicated primary antibodies. The proteins were developed with HRP-conjugated secondary antibody using ECL reagent as described [37,39].

### Real Time Quantitative RT-PCR

Total RNAs were prepared using TRIzol reagent as described previously [37,38,40]. First strand cDNAs were made with 1 mg RNA using oligo-dT and M-MuLV reverse transcriptase. The cDNA was amplified in a 96-well plate using collagen I ( $\alpha$ 2) primers (Forward: 5'-GGTCTGGATGGATTGAAGGGA-CAGC-3' and Reverse: 5'-GGCTCCTGTTTGACCTG-GAGTTCC-3') in a 7500 real time PCR machine (Applied Biosystem). The PCR conditions were 94°C for 10 minutes followed by 45 cycles at 94°C for 30 seconds, 58°C for 30 seconds and 72°C for 30 seconds. The level of mRNA was normalized by GAPDH in the same sample. Data were analyzed by comparative C<sub>t</sub> method as described [38].

### Transfection and Luciferase Assay

Cells were transfected with indicated plasmids or siRNA using FuGENE HD reagent according to vendor's protocol. For reporter assays, the reporter plasmids were transfected along with indicated expression plasmids and siRNA. The transfected cells were incubated with TGF $\beta$  as described in the legends to the Figures. The cell lysates were used to assay luciferase activity using a kit [5,39,41]. The data are presented as mean of luciferase activity per microgram protein as arbitrary units  $\pm$  SE of indicated measurements as described in the figure legends [42].

### Chromatin Immunoprecipitation Assay

Cell monolayer was used to prepare sheared chromatin essentially as described previously [43,44]. Sheared chromatin was incubated with protein G-plus Agarose. The cleared chromatin was used as the input control. Sheared chromatin was then incubated with nonimmune IgG or Hif1 $\alpha$  antibody to

immunoprecipitate the Hif1 $\alpha$ -bound DNA fragment along with protein G-plus Agarose. The eluted DNA from the immunoprecipitates was amplified with collagen I ( $\alpha 2$ ) primers (Forward: 5'-CGAGTCAGAGTTTCCCCTTGAAAGC-3' and Reverse: 5'-CGCAGAGGGGAGCGAATG-3') spanning the hypoxia responsive element (HRE). The product was analyzed by agarose gel electrophoresis. Also the PCR reaction was carried out in a real time PCR machine as described above. The PCR condition was: 94°C for 10 minutes followed by 40 cycles of 94°C for 30 seconds, 58°C for 30 seconds and 72°C for 30 seconds, respectively.

## Results

### TGF $\beta$ downregulates deptor to increase expression of collagen I ( $\alpha 2$ )

TGF $\beta$  increases expression of various matrix proteins including collagen I ( $\alpha 2$ ) in renal proximal tubular epithelial cells. We have shown previously that TGF $\beta$  rapidly activates both mTORC1 and mTORC2 [13,16]. TGF $\beta$ -stimulated increase in PI 3 kinase activity precedes the activation of both these complexes [13,16,45]. However, prolonged incubation of cells with TGF $\beta$  is required for collagen I ( $\alpha 2$ ) expression and rapamycin, a potent inhibitor of mTOR kinase activity, inhibited collagen I ( $\alpha 2$ ) expression (Fig. S1) [17,46]. Therefore, we investigated the mechanism of prolonged activation of mTOR necessary for collagen I ( $\alpha 2$ ) expression. Recently, a negative regulator of mTOR activity, deptor, has been identified [47]. Deptor is a common component of both mTORC1 and mTORC2. Since deptor maintains the basal activity of both these complexes, we investigated its expression in human proximal tubular epithelial cells, which accumulates collagen in response to TGF $\beta$ . Incubation of proximal tubular epithelial cells with TGF $\beta$  significantly inhibited the levels of deptor in a time-dependent manner till 24 hours (Fig. 1A and Fig. S2A). As deptor is an inhibitor of mTOR, we examined activation of mTORC1 employing phosphorylation of S6 kinase (Thr-389) and 4EBP-1 (Thr-37/46) as indicators. As shown in Figs. 1B and 1C, TGF $\beta$  increased the phosphorylation of S6 kinase and 4EBP-1 at same kinetics (Figs. S2B and S2C) as deptor downregulation. Similarly, TGF $\beta$  increased mTORC2 activity as determined by the phosphorylation of its substrate Akt at Ser-473 (Fig. 1D and Fig. S2D) [48]. Note that phosphorylation of Akt at Thr-308 was also increased by TGF $\beta$  (Fig. 1D). Together, these results suggest that TGF $\beta$ -induced deptor downregulation activates both mTORC1 and mTORC2 in a prolonged manner.

To determine the role of deptor in collagen I ( $\alpha 2$ ) expression, we used FLAG-tagged deptor expression vector in proximal tubular epithelial cells. Expression of deptor significantly inhibited both mTORC1 and mTORC2 activity induced by 24 hours incubation with TGF $\beta$  (Figs. 1E–1G and Figs. S2E–S2G). As expected, TGF $\beta$  increased the expression of collagen I ( $\alpha 2$ ) mRNA. Expression of deptor significantly inhibited TGF $\beta$ -induced collagen I ( $\alpha 2$ ) mRNA expression (Fig. 1H and Fig. S3A). Similarly, deptor attenuated collagen I ( $\alpha 2$ ) protein expression in response to TGF $\beta$  (Fig. 1I and Fig. S3B). To confirm the role of deptor, we used two independent shRNA vectors against deptor. Expression of both these shRNAs alone in proximal tubular epithelial cells increased phosphorylation of S6 kinase, 4EBP-1 (indicator of mTORC1) and Akt (indicator of mTORC2) similar to TGF $\beta$  treatment (Figs. 2A–2C and Fig. S4A–S4C). Importantly, both shRNAs against deptor significantly increased collagen I ( $\alpha 2$ ) mRNA expression similar to that with TGF $\beta$  alone (Fig. 2D and Fig. S5A). Similarly, deptor shRNAs alone were sufficient to significantly increase collagen I ( $\alpha 2$ ) protein level (Fig. 2E and Fig.

S5B). Deptor shRNAs did not have any significant additive effect when used along with TGF $\beta$  treatment (Figs. 2D and 2E), suggesting that TGF $\beta$  effects on the tested parameters were mediated via reduction in deptor. To confirm the role of deptor in collagen I ( $\alpha 2$ ) expression and to examine the specificity of deptor shRNA, we used mouse proximal tubular epithelial cells. shRNA against mouse deptor was transfected into these cells followed by incubation with TGF $\beta$ . We also performed rescue experiment in these mouse cells by transfecting FLAG-tagged human deptor, which is not recognized by the mouse deptor shRNA. The results show that mouse shDeptor significantly increased collagen I ( $\alpha 2$ ) expression similar to TGF $\beta$  treatment (Fig. S5C). Importantly, expression of mouse shDeptor-resistant human deptor inhibited mouse shDeptor-induced increase in collagen I ( $\alpha 2$ ) expression both in the absence and presence of TGF $\beta$  (Fig. S5C).


### Deptor regulates collagen I ( $\alpha 2$ ) transcription

We have shown above that deptor regulates expression of collagen I ( $\alpha 2$ ) mRNA (Figs. 1H and 2D). It has been reported previously that TGF $\beta$  regulates collagen I ( $\alpha 2$ ) expression by a transcriptional mechanism [46]. Therefore, we used a reporter plasmid where collagen I ( $\alpha 2$ ) promoter drives the luciferase gene. As expected, TGF $\beta$  increased the transcription of collagen I ( $\alpha 2$ ) (Fig. 3). Expression of deptor significantly decreased the TGF $\beta$ -induced transcription of collagen I ( $\alpha 2$ ) (Fig. 3A and Fig. S6A). Next, we used two independent shRNAs against deptor. Expression of either of these shRNAs increased the transcription of collagen I ( $\alpha 2$ ) similar to that found with TGF $\beta$  alone (Fig. 3B and Fig. S6B). Addition of TGF $\beta$  in deptor shRNA-transfected cells did not have any further increment as compared to TGF $\beta$  alone (Fig. 3B). This could be due to the fact that TGF $\beta$  may have maximized the effect so that shDeptor could not further increase the luciferase activity in these cells. These results indicate that deptor regulates collagen I ( $\alpha 2$ ) expression via a transcriptional mechanism and maintain a tonic inhibition on its gene expression in the basal state.


### Deptor regulates Hif1 $\alpha$ in renal proximal tubular epithelial cells by mRNA translation

TGF $\beta$  regulates the expression of collagen I ( $\alpha 2$ ) via Smad 3-dependent transcriptional activation [46,49]. Recently, it was shown that Hif1 $\alpha$  contributes to the Smad 3-dependent collagen I ( $\alpha 2$ ) expression [50]. To systematically initiate our studies involving the mechanism of deptor regulation of collagen I ( $\alpha 2$ ), we considered Hif1 $\alpha$  as a target transcription factor. TGF $\beta$  increased the expression of Hif1 $\alpha$  protein in human proximal tubular epithelial cells in a time-dependent manner (Fig. 4A and Fig. S7A). Interestingly, expression of deptor significantly inhibited TGF $\beta$ -induced Hif1 $\alpha$  expression at 24 hours (Fig. 4B and Fig. S7B). To confirm this observation, we used shRNAs against deptor. Using two independent shRNAs, we found that downregulation of deptor was sufficient to increase Hif1 $\alpha$  expression in these cells similar to TGF $\beta$  treatment (Fig. 4C and Fig. S7C). Interestingly, TGF $\beta$  did not increase Hif1 $\alpha$  mRNA (Fig. S8) Also, deptor over expression or deptor shRNAs had no effect on Hif1 $\alpha$  mRNA expression (Figs. S8A and S8B).


TSC2 null murine embryonic fibroblasts express increased levels of Hif1 $\alpha$  protein due to enhanced mTOR activity [51]. It was reported that this increase is due to augmented mRNA translation of Hif1 $\alpha$  as result of the presence of 5' terminal oligopyrimidines (5'TOP) in its untranslated region (UTR) [39,52]. We have shown above that TGF $\beta$ -induced deptor downregulation augments the activity of both mTORC1 and mTORC2 (Figs. 1A–1D). To determine the role of deptor in




**Figure 1. TGFβ-induced suppression of dector regulates collagen expression in proximal tubular epithelial cells.** (A–D) TGFβ decreases dector resulting in increased mTORC1 and mTORC2 activity. Human proximal tubular epithelial cells were incubated with 2 ng/ml TGFβ for indicated period of time. The cell lysates were immunoblotted with dector, actin (panel A), phospho-S6 kinase (Thr-389), S6 kinase (panel B), phospho-4EBP-1 (Thr-37/46), 4EBP-1 (panel C) and phospho-Akt (Ser-473), phospho-Akt (Thr-308) and Akt (panel D) antibodies as indicated. (E–G and I) Expression of dector inhibits mTORC1 and mTORC2 activities to block collagen expression. Human proximal tubular epithelial cells were transfected with FLAG-tagged Dector expression plasmid or vector. Transfected cells were incubated with 2 ng/ml TGFβ for 24 hours. The cell lysates were immunoblotted with phospho-S6 kinase, S6 kinase (panel E), phospho-4EBP-1, 4EBP-1 (panel F), phospho-Akt, Akt (panel G), collagen I (α2), actin (panel I) as indicated. The same lysates were used to immunoblot with FLAG antibody to demonstrate dector expression. Quantifications of panels A–G are shown in Fig. S2A–S2G. (H) Expression of dector inhibits mTORC1 and mTORC2 activities to block collagen mRNA expression. Human proximal tubular epithelial cells were transfected with FLAG-tagged Dector expression plasmid or vector. Transfected cells were incubated with 2 ng/ml TGFβ for 24 hours. Total RNAs were prepared and used for real time RT-PCR to detect collagen mRNA as described in the Materials and Methods. Mean ± SE of triplicate measurements is shown. \*p<0.01 vs control; \*\*p<0.01 vs TGFβ-treated. Expression of Dector in parallel samples is shown in Fig. S3A. Quantification of panel I is shown in Fig. S3B. doi:10.1371/journal.pone.0109608.g001



**Figure 2. shRNA-mediated repression of deptor increases mTORC1 and mTORC2 activity, resulting in collagen I ( $\alpha 2$ ) expression similar to TGF $\beta$ .** (A–C and E) Human proximal tubular epithelial cells were transfected with two independent shRNAs against deptor (Deptor sh1 and Deptor sh2). The transfected cells were incubated with 2 ng/ml TGF $\beta$  for 24 hours. The cell lysates were immunoblotted with indicated antibodies. Quantifications of panels A–C are shown in Figs. S4A–S4C. (D) Human proximal tubular epithelial cells were transfected with two independent shRNAs against deptor (Deptor sh1 and Deptor sh2). The transfected cells were incubated with 2 ng/ml TGF $\beta$  for 24 hours. Total RNA was prepared and used for real time RT-PCR to detect collagen I ( $\alpha 2$ ) mRNA as described in the Materials and Methods. Mean  $\pm$  SE of triplicate measurements is shown. \*p<0.01 vs control. Expression of Deptor in parallel samples is shown in Fig. S5A. Quantification of Fig. 2E is shown in Fig. S5B.



**Figure 3. TGFβ-induced deptor downregulation regulates collagen I (α2) transcription.** Collagen I (α2 promoter-driven luciferase reporter plasmid was co-transfected with FLAG-deptor (panel A) or shRNAs against deptor (Deptor sh1 and Deptor sh2) (panel B). The transfected cells were incubated with TGFβ for 24 hours. The cell lysates were assayed for luciferase activity as described in the Materials and Methods [5,39]. Mean ± SE of 3 measurements is shown. For panel A, \*p<0.01 vs control; \*\*p<0.01 vs TGFβ-stimulated. For panel B left part, \*p<0.01 vs control; \*\*p<0.05 vs control. For panel B right part, \*p<0.05 vs control. Expression of deptor for these panels in parallel samples is shown in Fig. S6. doi:10.1371/journal.pone.0109608.g003



**Figure 4. TGFβ-inhibited deptor regulates Hif1α expression.** (A) Human proximal tubular epithelial cells were incubated with 2 ng/ml TGFβ for indicated period of time. The cell lysates were immunoblotted with Hif1α and actin antibodies. (B and C) Human proximal tubular epithelial cells transfected with FLAG-Deptor (panel B) or shRNAs against deptor (Deptor sh1 and Deptor sh2) were incubated with TGFβ for 24 hours (panel C). The cell lysates were immunoblotted with Hif1α, deptor, actin and FLAG antibodies as indicated. Quantifications of panel A–C are shown in Fig. S7A–S7C. doi:10.1371/journal.pone.0109608.g004

regulation of Hif1 $\alpha$  protein levels via mRNA translation, we used a reporter construct in which the 5' UTR of Hif1 $\alpha$  mRNA is fused to the Renilla luciferase gene (Hif1 $\alpha$ -TOP-Lux). This reporter plasmid was transfected into proximal tubular epithelial cells. TGF $\beta$  significantly increased Hif1 $\alpha$ -5'UTR-mediated luciferase activity (Fig. 5). Interestingly, expression of deptor significantly inhibited the Hif1 $\alpha$ -5'UTR-mediated reporter activity (Fig. 5A and Fig. S9A). In contrast, expression of two independent shRNAs against deptor was sufficient to increase the reporter activity similar to TGF $\beta$  treatment (Fig. 5B and Fig. S9B). Deptor shRNAs in the presence of TGF $\beta$  did not further increase the luciferase activity. These results suggest that deptor increases Hif1 $\alpha$  protein level via increased translation of Hif1 $\alpha$  mRNA.


### Deptor regulates Hif1 $\alpha$ interaction with collagen I ( $\alpha$ 2) gene

Hif1 $\alpha$  has been shown to regulate collagen I ( $\alpha$ 2) expression by TGF $\beta$ -stimulated Smad 3 [50]. However, analysis of the 5' flanking sequence of collagen I ( $\alpha$ 2) gene revealed the presence of Hif1 $\alpha$  responsive element (HRE) between the putative transcription start site and the start codon (Fig. 6A). To determine whether endogenous Hif1 $\alpha$  occupies this site in the collagen I ( $\alpha$ 2) gene, we performed ChIP assay. As shown in Fig. 6B, we detected physical


association of Hif1 $\alpha$  with the HRE present in the collagen I ( $\alpha$ 2) 5' flanking sequence. Next, we determined the effect of TGF $\beta$  on binding of endogenous Hif1 $\alpha$  to this site. TGF $\beta$  significantly increased the binding of Hif1 $\alpha$  to its cognate binding element (Figs. 6C, 6D). Interestingly, expression of deptor significantly inhibited the binding of Hif1 $\alpha$  to the 5' flanking sequence of collagen I ( $\alpha$ 2) gene (Fig. 6C and S10A). To confirm this effect of deptor, we used shRNAs against deptor. Two independent shRNAs significantly increased the Hif1 $\alpha$  occupancy onto the collagen I ( $\alpha$ 2) 5' flanking sequence similar to that with TGF $\beta$  (Fig. 6D and Fig. S10B). Addition of TGF $\beta$  to the shRNA-transfected cells did not further increase the binding of Hif1 $\alpha$  (Fig. 6D). These results conclusively demonstrate that TGF $\beta$ -induced decrease in deptor expression results in marked recruitment of Hif1 $\alpha$  to the collagen I ( $\alpha$ 2) gene.

### Deptor-regulated mTORC1 and not mTORC2 increases Hif1 $\alpha$ to control collagen I ( $\alpha$ 2) expression

Our results above suggest that downregulation of deptor by TGF $\beta$  increases Hif1 $\alpha$  levels and that this is associated with elevated collagen I ( $\alpha$ 2) expression in proximal tubular epithelial cells. To determine the direct involvement of Hif1 $\alpha$  in collagen I ( $\alpha$ 2) expression by deptor modulation, we transfected proximal



**Figure 5. TGF $\beta$ -induced Hif1 $\alpha$  expression is translationally regulated by deptor expression.** Human proximal tubular epithelial cells were cotransfected with the Hif1 $\alpha$  5'UTR-fused Renilla luciferase and FLAG-Deptor (panel A) or deptor shRNAs (panel B). The transfected cells were treated with TGF $\beta$  for 24 hours. The cell lysates were used to assay Renilla luciferase activity as described [5,39]. In panel A, Mean  $\pm$  SE of 5 measurements is shown. \* $p$ <0.001 vs control; \*\* $p$ <0.001 vs TGF $\beta$ -stimulated. In panel B, Mean  $\pm$  SE of 3 measurements is shown. \* $p$ <0.05 vs control. Expression of deptor for these panels from parallel samples is shown in Fig. S9. doi:10.1371/journal.pone.0109608.g005




**Figure 6. TGFβ-inhibited deceptor regulates Hif1α binding to its cognate HRE in collagen I (α2) gene.** (A) The sequence showing the HRE (bases denoted in red and underlined), the start codon (in blue) and the transcription initiation site (in green and indicated by arrow) of the collagen gene. (B) Chromatin immunoprecipitation assay to determine binding of Hif1α to collagen gene. Fragmented chromatin from proximal tubular epithelial cells were incubated with IgG or anti-Hif1α antibody as described in the Materials and Methods. The bound DNA was eluted and amplified with collagen gene specific primers flanking the HRE shown in panel A as described in Materials and Methods. (C and D) The cells were transfected with FLAG-deptor (panel C) or shRNAs against deceptor (panel D). The transfected cells were incubated with TGFβ. Fragmented chromatin preparations were used for ChIP assay as described in panel B except the amplification was performed by real time PCR as described under Materials and Methods. Relative amount of bound Hif1α was calculated by the ratio of ChIPed DNA to input control DNA. Mean ± SE of triplicate measurements is shown. In panel C, \*p<0.01 vs control; \*\*p<0.01 vs TGFβ-treated. In panel D, left panel \*p<0.001 vs control. In panel D right panel, \*p<0.01 vs TGFβ; \*\*p<0.05 vs control. Expression of deceptor for panel C and D is shown in parallel samples in Fig. S10. doi:10.1371/journal.pone.0109608.g006

tubular epithelial cells with deceptor shRNAs along with siRNA against Hif1α. The cells were then incubated with TGFβ. As expected, TGFβ as well as shRNAs against deceptor alone increased the collagen I (α2) protein levels (Figs. 7A). Interestingly, expression of siRNA against Hif1α significantly inhibited the expression of collagen I (α2) induced by TGFβ and shRNA-mediated downregulation of deceptor individually as well as with TGFβ in the presence of deceptor downregulation (Figs. 7A and Fig. S11A). To determine the transcriptional regulation, we used the collagen I (α2) promoter-reporter construct. Similar to the collagen I (α2) protein expression, siHif1α significantly decreased TGFβ- and Deceptor shRNA-mediated collagen I (α2) transcription (Figs. 7B and Fig. S11B). Also siHif1α reduced the transcription of collagen I (α2) induced by combined action of Deceptor shRNAs and TGFβ (Figs. 7B). These results conclusively demonstrate that TGFβ-induced deceptor downregulation-mediated expression of collagen I (α2) utilizes Hif1α.

Deceptor is a component of both mTORC1 and mTORC2 [47]. We have shown above that TGFβ-induced inhibition of deceptor increases activity of both these kinase complexes (Figs. 1A–1D). However, it is not known whether deceptor utilizes both mTORC1 and mTORC2 to induce the expression of collagen I (α2) in response to TGFβ. To examine the contribution of mTORC1 in this process, we used shRNA against raptor, which is essential for mTORC1 activity [20,21]. Raptor shRNA was transfected with deceptor shRNAs and the cells were incubated with TGFβ. As expected, Deceptor shRNA alone and along with TGFβ increased the expression of collagen I (α2) (Fig. 8A and Fig. S12A). But expression of shRaptor significantly inhibited both shDeceptor- and shDeceptor plus TGFβ-induced collagen I (α2) expression, which was concomitant with decrease in expression of Hif1α (Figs. 8A, 8B and Figs. S12A and S12B). To study the role of mTORC2, we used shRNA targeting rictor, a required constituent of mTORC2 activity [53]. Expression of shRictor did not have any inhibitory






**Figure 7. TGFβ-induced collagen expression by deptor downregulation is mediated by Hif1α.** (A) Human proximal tubular epithelial cells were transfected with deptor shRNAs and siRNA against Hif1α. The transfected cells were incubated with TGFβ for 24 hours. The cell lysates were immunoblotted with collagen I (α2), deptor, Hif1α and actin antibodies as indicated. Quantifications of panel A is shown in Fig. S11A. (B) Collagen I (α2) promoter-driven luciferase reporter plasmid was co-transfected with deptor shRNAs (Deptor sh1 and Deptor sh2) and siRNA against Hif1α. The transfected cells were incubated with TGFβ for 24 hours. The cell lysates were assayed for luciferase activity as described in the Materials and Methods [5,39]. In panel B left panel, \*p<0.001 vs control; \*\*p<0.01 vs TGFβ-treated; #p<0.01 vs Deptor shRNAs alone; @p<0.001 vs shRNA against deptor plus TGFβ. In panel B right panel, \*p<0.001 vs control; \*\*p<0.05 vs TGFβ-treated; #p<0.05 vs Deptor shRNAs alone; @p<0.05 vs shRNA against deptor plus TGFβ. Expression of deptor and Hif1α for panel B is shown in Fig. S711B. doi:10.1371/journal.pone.0109608.g007

effect on expression of collagen I (α2) by TGFβ or shDeptor alone or in combination (Fig. 8C and Fig. S12C). Similarly shRictor did not inhibit Hif1α expression induced by TGFβ or shDeptor alone or in combination (Fig. 8D and Fig. S12D). To confirm the role of mTORC1 in collagen I (α2) expression, we used the reporter construct with collagen I (α2) promoter. Downregulation of raptor inhibited the transcription of collagen I (α2) stimulated by TGFβ, shDeptor and shDeptor with TGFβ (Fig. 9A and S13A). In contrast, inhibition of rictor did not have any effect on collagen I (α2) transcription (Fig. 9B and Fig. S13B). These results indicate a preferential use of mTORC1 over mTORC2 downstream of deptor downregulation by TGFβ to increase collagen I (α2) expression.

**Discussion**

In this report, we provide the first evidence that TGFβ-induced deptor downregulation contributes to fibrotic gene collagen I (α2) expression by a transcriptional mechanism. Our results demonstrate that deptor downregulation by TGFβ increases Hif1α translation to increase its protein level, which subsequently binds to its cognate HRE in the collagen I (α2) gene to increase its transcription. Finally, we show that TGFβ-stimulated mTORC1 and not mTORC2 downstream of deptor downregulation contributes to increased expression of Hif1α and collagen I (α2) (Fig. 10).

Canonical TGFβ-stimulated Smad 3 signaling has been shown to regulate fibrotic gene expression [54]. However, cross-talk between the noncanonical PI 3 kinase/Akt signaling and Smad 3 is required for expression of two matrix proteins fibronectin and collagen I (α2) [13,46]. Recently, we and others have shown that in diabetic kidney disease in which TGFβ plays a significant role to produce extracellular matrix, administration of rapamycin, which inhibits both mTORC1 and mTORC2 in mice, resulted in marked reduction in matrix proteins including collagen I (α2) [33,34,55,56]. Rapamycin also inhibits basal and TGFβ-induced expression of collagen I (α2) in renal glomerular mesangial cells and proximal tubular epithelial cells (Fig. S1) [17]. Homozygous deletion of mTOR in mice is embryonically lethal indicating its importance in normal physiology [57]. PI 3 kinase/mTOR activity is essential for normal physiological function of renal cells [58]. When patients with chronic allograft nephropathy were changed from calcineurin to rapamycin treatment, 62% of them showed new onset of proteinuria [59]. In fact 36% showed nephritic level proteinuria. In another study, one third of the patients showed *de novo* 1 g/day proteinuria when switched to rapamycin [60]. Also, renal transplant patients treated with rapamycin show increased proteinuria due to renal damage including tubular damage [61]. In animals with puromycin aminonucleoside-induced nephrotoxicity, treatment with rapamycin produced loss of renal function [62]. More recently using renal podocyte-specific raptor knockout mice, Godel et al have reported




**Figure 8. TGFβ-induced deceptor downregulation uses mTORC1 and not mTORC2 to increased collagen I (α2) and Hif1α expression.** (A and B) Human proximal tubular epithelial cells were transfected with deceptor shRNAs (deptor sh1 and deceptor sh2) along with shRNA against raptor. The transfected cells were incubated with TGFβ for 24 hours. The cell lysates were immunoblotted with collagen (α2) (panel A), Hif1α (panel B) and raptor, deceptor, actin antibodies as indicated. (C and D) The cells were transfected with deceptor shRNAs (Deptor sh1 and Deptor sh2) along with shRNA against rictor. The cell lysates were immunoblotted with collagen I (α2) (panel C), Hif1α (panel D) and rictor, deceptor, actin antibodies as indicated. Quantifications of Fig. 8 are shown in Figs. S12A–S12D. doi:10.1371/journal.pone.0109608.g008


severe proteinuria at early stage [63]. These results indicate that complete loss of mTOR is detrimental to the normal homeostasis of renal cells.

Deptor was identified as an mTOR interacting protein [47]. The C-terminal PDZ segment of deceptor interacts with the FAT domain of mTOR and prevents the kinase activity of mTOR present in both mTORC1 and mTORC2 [47]. Thus deceptor represents a natural inhibitor, which maintains the basal activity of

both kinase complexes. Increased mTOR kinase activity represents a major pathology in many cancers [21]. It was shown that the level of deceptor is significantly low in many cancers [47,64]. In fact, deceptor inhibition was the sole cause for resistance of cancer cells to apoptosis [47]. Sustained activation of mTOR is seen in fibrotic renal diseases such as diabetic nephropathy in which TGFβ plays an important role in developing fibrosis [30,31,32,33,34,65]. Interestingly, TGFβ inhibits deceptor expres-



**Figure 9. Deptor downregulation by TGFβ uses mTORC1 and not mTORC2 to increase transcription of collagen I (α2).** Human proximal tubular epithelial cells were transfected with collagen I (α2) promoter-driven luciferase plasmid along with deptor shRNAs and shRNA against raptor (panel A) or shRNA for rictor (panel B). The transfected cells were incubated with TGFβ for 24 hours. The cell lysates were assayed for luciferase activity as described in the Materials and Methods [5,39]. Mean ± SE of triplicate measurements is shown. In panel A left part, \*p<0.001 vs control; \*\*p<0.05 vs TGFβ; @p<0.05 vs shDeptor alone; #p<0.01 vs shDeptor plus TGFβ. In panel B, \*p<0.01 vs control. In panel A right panel, \*p<0.01 vs control; \*\*p<0.01 vs TGFβ; @p<0.01 vs shDeptor alone; #p<0.01 vs shDeptor plus TGFβ. In panel B left panel, \*p<0.01 vs control; \*\*p<0.05 vs TGFβ. In panel B right panel, \*p<0.001 vs control; \*\*p<0.05 vs control; @p<0.01 vs control. Expression of deptor, raptor and rictor for all panels is shown in Fig. S13A and S13B. doi:10.1371/journal.pone.0109608.g009



**Figure 10. Cartoon summarizes the results demonstrating the involvement of deptor and mTORC1 in Hif1α expression for collagen I (α2) expression in response to TGFβ.** doi:10.1371/journal.pone.0109608.g010

sion with concomitant increase in both mTORC1 and mTORC2 activities (Fig. 1A–1D). Moreover, suppression of deptor by prolonged incubation with TGFβ contributes to the expression of collagen I (α2) by a transcriptional mechanism (Figs. 1–3).

Although deptor inhibits the activity of both mTORC1 and mTORC2, two other proteins, tuberin and PRAS40, negatively regulate the activity of the mTORC1 [66,67]. Inactivation of PRAS40 and tuberin by Akt-mediated phosphorylation results in increased mTORC1 activity. We have shown recently that rapid activation of mTORC1 in renal cells involves phosphorylation/inactivation of these two proteins [16,38,42,68]. However, expression of deptor did not have any effect on phosphorylation of tuberin and PRAS40 when the proximal tubular epithelial cells were incubated with TGFβ for 15 minutes (rapid activation) (Figs. S14A and S14B). Consequently, deptor did not inhibit TGFβ-stimulated early mTORC1 activation as indicated by phosphorylation of S6 kinase and 4EBP-1 (Figs. S15A and S15B). Similarly, expression of deptor had no effect on TGFβ-induced phosphorylation of Akt at Ser-473, indicator of mTORC2 activation (Fig. S16). In contrast to these results we found significant inhibition of prolonged activation of both mTORC1 and mTORC2 by deptor, which results in attenuation of collagen I (α2) expression (Figs. 1E–1I). Mechanistically, activation of mTORC1 involves phosphor-

ylation of both PRAS40 and tuberlin. In fact, we found that expression of deptor blocked phosphorylation of both PRAS40 and tuberlin when the cells were incubated with TGF $\beta$  for prolonged period of time (Figs. S17A and S17B). These results indicate that TGF $\beta$  induces a deptor-independent rapid activation of mTOR; however, expression of collagen I ( $\alpha$ 2) requires deptor-mediated activation of mTOR induced by prolonged TGF $\beta$  treatment (Fig. 1H, 1I, Fig. 2D, 2E and Fig. 3).

The transcription factor Hif1 is a heterodimer of Hif1 $\alpha$  and Hif1 $\beta$ . This complex formation is regulated by the availability of Hif1 $\alpha$  subunit, which is sensitive to normoxia and undergoes degradation by the proline hydroxylase domain proteins [69]. Level of Hif1 $\alpha$  is significantly elevated by hypoxia, which undergoes phosphorylation by ATM to increase REDD1 that activates the tuberous sclerosis complex and results in inhibition of mTORC1 activity [70,71,72]. In addition to hypoxia, oncogenes, mutations in metabolic enzyme genes and tumor suppressor genes can cause upregulation of Hif1 $\alpha$  protein [73,74,75]. Also, increased Hif1 $\alpha$  level is present in cells with activated mTORC1 due to mutation in TSC1 or TSC2 which removes negative regulatory constraint on Rheb-GTP necessary for mTORC1 activation [20,21,51]. More recently, analysis of genome sequence of 750 cancer samples including renal cancer identified several point mutations in the C-terminus of mTOR. Two of these point mutants showed constitutive mTORC1 activity without any increase in mTORC2 activity [76,77]. All these modes of mTORC1 activation result in increased Hif1 $\alpha$  levels due to enhanced 5'TOP mRNA translation of Hif1 $\alpha$  [36,51,78]. However, a recent study revealed a role of mTORC2 in Hif1 $\alpha$  expression [79]. In the present study, downregulation of deptor by TGF $\beta$ , which increases both mTORC1 and mTORC2 activities, increased the levels of Hif1 $\alpha$  in a prolonged manner (Fig. 4A). Also, our results for the first time demonstrate that deptor regulates TGF $\beta$ -induced expression of Hif1 $\alpha$  (Fig. 4B–4D). The deptor-regulated increase in Hif1 $\alpha$  is the result of increased translation of 5'TOP containing Hif1 $\alpha$  mRNA (Fig. 5).

The role of Hif1 $\alpha$  in cancer is extensively studied, where upregulation of all 13 glycolytic genes to exert Warburg effect is under the influence of this transcription factor [80]. In addition, Hif1 $\alpha$  supports angiogenesis by increasing the expression of VEGF under hypoxic and normoxic conditions [51,69,80]. Also, we have shown that in the hamartoma syndrome tuberous sclerosis, normoxic elevation of mTOR activity enhances the PTEN tumor suppressor gene expression via upregulation of Hif1 $\alpha$  [39,41]. Furthermore, Hif1 $\alpha$  has been implicated in the pathogenesis of atherosclerosis [81]. Hif1 $\alpha$  can physically interact with various transcription factors to increase the expression of the target genes. In fact, Hif1 $\alpha$  has been shown to physically interact with the TGF $\beta$ -specific Smad3 transcription factor to increase expression of VEGF, collagen I ( $\alpha$ 2) and endoglin [50,80,82,83]. Interestingly, we identified a Hif1 $\alpha$  responsive element in the collagen I ( $\alpha$ 2) gene between the transcription initiation site and start codon (Fig. 6A). For the first time, we show that Hif1 $\alpha$  directly binds to this site in proximal tubular epithelial cells (Fig. 6B). Furthermore, we provide evidence for a direct role of deptor in mediating Hif1 $\alpha$  binding to this site (Figs. 6C and 6D). In fact, we demonstrate that deptor-regulated expression of collagen I ( $\alpha$ 2) protein is indeed mediated by Hif1 $\alpha$ -dependent transcription (Figs. 7A and 7B).

As described above, deptor constitutively binds to mTOR; consequently it is present in both mTORC1 and mTORC2 [47]. Interestingly, it was shown previously that when overexpressed, deptor inhibited only mTORC1 and increased mTORC2 activity, which is necessary for maintenance of certain cancers such as multiple myeloma [47]. In contrast to these results, in the present

study when deptor was overexpressed in proximal tubular epithelial cells, it inhibited mTORC2 activity induced by TGF $\beta$  (Fig. 1G). Thus our results demonstrate that deptor regulates both mTORC1 and mTORC2 activities in proximal tubular epithelial cells (Figs. 1E, 1F and 1G). We also show that deptor controls the expression of collagen I ( $\alpha$ 2) gene in response to TGF $\beta$  by a transcriptional mechanism (Figs. 2 and 3). Importantly, when we specifically inhibited mTORC1 activity the increase in collagen I ( $\alpha$ 2) protein expression and its transcription by deptor downregulation or TGF $\beta$  alone or in combination was significantly inhibited (Figs. 8A and 9A). Furthermore, inhibition of mTORC1 alone blocked TGF $\beta$ - and shDeptor-induced Hif1 $\alpha$  protein levels (Fig. 8B). Interestingly, when mTORC2 activity was inhibited by rictor downregulation, there was no effect of TGF $\beta$ -induced suppression of deptor on collagen I ( $\alpha$ 2) protein expression and transcription (Figs. 8C and 9B). Also, Hif1 $\alpha$  expression was unaffected (Fig. 8D). These results conclusively suggest that mTORC2, although activated by TGF $\beta$ -mediated downregulation of deptor, acts as a bystander and does not contribute to the expression of collagen I ( $\alpha$ 2). Use of rapamycin to inhibit mTORC1 produces adverse side effects in the kidney [59,60,61,62]. Many other direct mTOR kinase inhibitors are being developed; however, they display severe toxicity. Since decrease in deptor contributes to the pathologic action of TGF $\beta$  to increase expression of tubular collagen I ( $\alpha$ 2), development of safe compounds that increase the levels of deptor, resulting in inhibition of mTORC1, may be beneficial for fibrotic renal diseases.

## Supporting Information

**Figure S1 Rapamycin inhibits TGF $\beta$ -induced collagen I ( $\alpha$ 2) expression in human proximal tubular epithelial cells.** The cells were treated with 25 nM rapamycin for 1 hour prior to incubation with 2 ng/ml TGF $\beta$  for 24 hours. The cell lysates were immunoblotted with collagen I ( $\alpha$ 2) and actin antibodies. (PDF)

**Figure S2 Quantification of the results shown in Figs. 1A–1G.** (A) Ratio of deptor to actin. Mean  $\pm$  SE of 3 independent experiments is shown. \* $p$ <0.01 vs 0 hour. (B) Ratio of phospho-S6 kinase to S6 kinase. Mean  $\pm$  SE of 3 independent experiments is shown. \* $p$ <0.01 vs 0 hour. (C) Ratio of phospho-4EBP-1 to 4EBP-1. Mean  $\pm$  SE of 3 independent experiments is shown. \* $p$ <0.001 vs 0 hour. (D) Ratio of phospho-Akt (Ser-473) (left panel) and phospho-Akt (Thr-308) (right panel) to Akt. Mean  $\pm$  SE of 3 independent experiments is shown. \* $p$ <0.001 vs 0 hour. (E) Ratio of phospho-S6 kinase to S6 kinase. Mean  $\pm$  SE of 5 independent experiments is shown. \* $p$ <0.001 vs vector; \*\* $p$ <0.01 vs TGF $\beta$ -stimulated. (F) Ratio of phospho-4EBP-1 to 4EBP-1. Mean  $\pm$  SE of 5 independent experiments is shown. \* $p$ <0.001 vs vector; \*\* $p$ <0.01 vs TGF $\beta$ -treated. (G) Ratio of phospho-Akt (Ser-473) (left panel) and phospho-Akt (Thr-308) (right panel) to Akt. Mean  $\pm$  SE of 4 independent experiments is shown. \* $p$ <0.001 vs vector; \*\* $p$ <0.01 vs TGF $\beta$ -treated. (PDF)

**Figure S3 Expression of deptor for the results shown in Figure 1H, (A).** Human proximal tubular epithelial cells were transfected with FLAG-Deptor expression vector prior to incubation with 2 ng/ml TGF $\beta$  as described in the legend of Fig. 1H. The cell lysates were immunoblotted with FLAG and actin antibodies. (B) Quantification of the results shown in Fig. 1I. Ratio of collagen I ( $\alpha$ 2) to actin. Mean  $\pm$  SE of 4 independent

experiments is shown. \* $p < 0.01$  vs vector; \*\* $p < 0.01$  vs TGF $\beta$ -treated.  
(PDF)

**Figure S4 Quantification of the results shown in Figs. 2A–2C.** (A) Ratio of phospho-S6 kinase to S6 kinase. Mean  $\pm$  SE of 4 independent experiments is shown. \* $p < 0.001$  vs vector. (B) Ratio of phospho-4EBP-1 to 4EBP-1 is shown. Means  $\pm$  SE of 5 for left and 4 experiments for right panels respectively are shown. \* $p < 0.001$  vs vector. (C) Ratio of phospho-Akt to Akt is shown. Means  $\pm$  SE of 4 for left and 5 experiments for right panels respectively are shown. \* $p < 0.001$  vs vector.  
(PDF)

**Figure S5 Expression of deceptor for the results shown in Figure 2D, (A).** Human proximal tubular epithelial cells were transfected with expression vectors containing shRNAs against deceptor (Deceptor sh1 and Deceptor sh2) prior to incubation with 2 ng/ml TGF $\beta$  as described in the legend of Fig. 2D. The cell lysates were immunoblotted with deceptor and actin antibodies. (B) Quantification of the results shown in Fig. 2E. Ratio of collagen I ( $\alpha 2$ ) to actin is shown. Means  $\pm$  SE of 4 independent experiments are shown. \* $p < 0.001$  vs vector alone. (C) Rescue of deceptor downregulation by human deceptor expression in mouse proximal tubular epithelial cells to show specificity of deceptor shRNA. Mouse proximal tubular epithelial cells were transfected with shRNA against mouse deceptor along with FLAG-tagged human deceptor expression vector as indicated. The cells were incubated with TGF $\beta$  for 24 hours. Expression of collagen I ( $\alpha 2$ ), endogenous deceptor, FLAG-tagged human deceptor and actin are shown.  
(PDF)

**Figure S6 Expression of deceptor for the results shown in Figure 3.** Human proximal tubular epithelial cells were transfected with expression vectors containing FLAG-Deceptor (Panel A) or shRNAs against deceptor (Panel B) prior to incubation with TGF $\beta$  as described in the legend of Fig. 3. The cell lysates were immunoblotted with FLAG and actin antibodies (Panel A) and deceptor and actin antibodies (Panel B).  
(PDF)

**Figure S7 Quantification of the results shown in Fig. 4.** (A) Ratio of Hif1 $\alpha$  to actin. Mean  $\pm$  SE of 3 independent experiments is shown. For increase in 2 hours, \* $p < 0.05$  vs 0 hour; for increase in 4–24 hours \* $p < 0.01$  vs 0 hour. (B) Ratio of Hif1 $\alpha$  to actin. Mean  $\pm$  SE of 4 independent experiments is shown. \* $p < 0.001$  vs vector; \*\* $p < 0.001$  vs TGF $\beta$ -treated. (C) Ratio of Hif1 $\alpha$  to actin. Mean  $\pm$  SE of 4 independent experiments is shown. \* $p < 0.05$  vs vector alone for left panel; \* $p < 0.001$  vs vector for the right panel.  
(PDF)

**Figure S8 TGF $\beta$  does not regulate Hif1 $\alpha$  mRNA expression.** Human proximal tubular epithelial cells were transfected with FLAG-tagged Deceptor expression vector (panel A) or Deceptor sh1 or sh2 (panel B) as indicated followed by incubation with 2 ng/ml TGF $\beta$  for 24 hours. Expression of Hif1 $\alpha$  mRNA was determined by real time RT-PCR as described in the Materials and Methods. Mean  $\pm$  SE of triplicate measurements is shown. Bottom panels show FLAG-tagged deceptor (panel A), deceptor (panel B) and actin expression in parallel samples.  
(PDF)

**Figure S9 Expression of deceptor for the results shown in Figure 5.** Human proximal tubular epithelial cells were transfected with expression vectors containing FLAG-Deceptor (Panel A)

or shRNAs against deceptor (Panel B) prior to incubation with TGF $\beta$  as described in the legend of Fig. 5. The cell lysates were immunoblotted with FLAG and actin antibodies (Panel A) and deceptor and actin antibodies (Panel B).  
(PDF)

**Figure S10 Expression of deceptor for the results shown in Figure 6C and 6D.** Human proximal tubular epithelial cells were transfected with expression vectors containing FLAG-Deceptor (Panel A) as described in Fig. 6C or shRNAs against deceptor (Panel B) as described in Fig. 6D prior to incubation with TGF $\beta$ . The cell lysates were immunoblotted with FLAG and actin antibodies (Panel A) and deceptor and actin antibodies (Panel B).  
(PDF)

**Figure S11 Quantification of the results shown in Fig. 7A.** (A) Ratio of collagen I ( $\alpha 2$ ) to actin. Mean  $\pm$  SE of 4 independent experiments is shown. \* $p < 0.001$  vs vector alone. \*\* $p$ , @ $p$ , # $p < 0.001$  vs TGF $\beta$ , shDeceptor and shDeceptor plus TGF $\beta$ , respectively. (B) Expression of deceptor and Hif1 $\alpha$  for the results shown in Figure 7B. Human proximal tubular epithelial cells were transfected with vector or scramble RNA (Scr) or shRNAs against deceptor (Deceptor sh1 and Deceptor sh2) along with siRNA against Hif1 $\alpha$  prior to incubation with TGF $\beta$  as described in the legend of Fig. 7B. The cell lysates were immunoblotted with deceptor, Hif1 $\alpha$  and actin antibodies.  
(PDF)

**Figure S12 Quantification of the results shown in Fig. 8.** Ratios of collagen I ( $\alpha 2$ ) to actin for Fig. 8A and 8C (panels A and C) and ratio of Hif1 $\alpha$  to actin for Fig. 8B and 8D (panels B and D) are shown. Means  $\pm$  SE of 4 independent experiments are shown for A–C and for left panel of D. For panel D right panel, mean  $\pm$  SE of 5 experiments is shown. For panels A and B, \* $p < 0.001$  vs vector alone. \*\* $p$ , @ $p$ , # $p < 0.001$  vs TGF $\beta$ , shDeceptor and shDeceptor plus TGF $\beta$ , respectively. For panels C and D, \* $p < 0.001$  vs vector alone.  
(PDF)

**Figure S13 Expression of raptor, rictor, deceptor, and activation of mTORC1 (phospho-S6 kinase) and activation of mTORC2 (phosphorylation of Akt at Ser-473) for the results shown in Figure 9.** Human proximal tubular epithelial cells were transfected with vector or deceptor shRNA expression plasmids along with raptor shRNA (Panel A) or rictor shRNA (Panel B) prior to incubation with TGF $\beta$  as described in the legend of Fig. 9. The cell lysates were immunoblotted against raptor, phospho-S6 kinase (Thr-389), S6 kinase (panel A), rictor, phospho-Akt (Ser-473), Akt (Panel B), deceptor and actin antibodies as indicated.  
(PDF)

**Figure S14 Expression of deceptor does not inhibit rapid phosphorylation of Akt substrates PRAS40 and tuberin in response to TGF $\beta$ .** Human proximal tubular epithelial cells were transfected with vector or FLAG-Deceptor. The transfected cells were incubated with 2 ng/ml TGF $\beta$  for 15 minutes. The cell lysates were immunoblotted with phospho-PRAS40 (Thr-246), PRAS40 (Panel A) and phospho-tuberin (Thr-1462), tuberin (Panel B) antibodies. Expression of deceptor was detected by FLAG immunoblot.  
(PDF)

**Figure S15 Expression of deceptor does not inhibit rapid activation of mTORC1 in response to TGF $\beta$ .** Human proximal tubular epithelial cells were transfected with vector or FLAG-Deceptor. The transfected cells were incubated with 2 ng/ml

TGFβ for 15 minutes. The cell lysates were immunoblotted with antibodies for phospho-S6 kinase (Thr-389) (panel A) and phospho-4EBP-1 (Thr-37/46) (panel B) as indicators of mTORC1 activation. The lysates were also immunoblotted with FLAG antibody and S6 kinase (Panel A) and 4EBP-1 (Panel B) antibodies. (PDF)

**Figure S16 Expression of deceptor does not inhibit rapid activation of mTORC2.** Human proximal tubular epithelial cells were transfected with vector or FLAG-Deceptor. The transfected cells were incubated with 2 ng/ml TGFβ for 15 minutes. The cell lysates were immunoblotted with phospho-Akt (Ser-473) antibody as indicator of mTORC2 activation. The lysates were also immunoblotted with FLAG and Akt antibodies. (PDF)

**Figure S17 Expression of deceptor inhibits phosphorylation of Akt substrates PRAS40 and tuberlin in response to**

**prolonged TGFβ incubation.** Human proximal tubular epithelial cells were transfected with vector or FLAG-Deceptor. The transfected cells were incubated with 2 ng/ml TGFβ for 24 hours. The cell lysates were immunoblotted with phospho-PRAS40 (Thr-246), PRAS40 (Panel A) and phospho-tuberlin (Thr-1462), tuberlin (Panel B) antibodies. Expression of deceptor was detected by FLAG immunoblot. (PDF)

**Table S1 List of antibodies used in this study.** (PDF)

## Author Contributions

Conceived and designed the experiments: GGC. Performed the experiments: FD AB. Analyzed the data: FD AB GGC. Wrote the paper: GGC. Intellectual input and corrected the manuscript: NGC HEA BSK.

## References

- Bohle A, Mackensen-Haen S, von Gise H (1987) Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: a morphometric contribution. *Am J Nephrol* 7: 421–433.
- Massague J (2000) How cells read TGF-beta signals. *Nat Rev Mol Cell Biol* 1: 169–178.
- Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell* 113: 685–700.
- Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL (1998) SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. *Cell* 95: 779–791.
- Das F, Ghosh-Choudhury N, Venkatesan B, Li X, Mahimainathan L, et al. (2008) Akt kinase targets association of CBP with SMAD 3 to regulate TGFbeta-induced expression of plasminogen activator inhibitor-1. *J Cell Physiol* 214: 513–527.
- Miyazono K (2009) Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. *Proc Jpn Acad Ser B Phys Biol Sci* 85: 314–323.
- Moustakas A, Heldin CH (2009) The regulation of TGFbeta signal transduction. *Development* 136: 3699–3714.
- Meng XM, Huang XR, Chung AC, Qin W, Shao X, et al. (2010) Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. *J Am Soc Nephrol* 21: 1477–1487.
- Samarakoon R, Higgins CE, Higgins SP, Kutz SM, Higgins PJ (2005) Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent. *J Cell Physiol* 204: 236–246.
- Samarakoon R, Higgins SP, Higgins CE, Higgins PJ (2008) TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. *J Mol Cell Cardiol* 44: 527–538.
- Finer G, Schnaper HW, Kanwar YS, Liang X, Lin HY, et al. (2012) Divergent roles of Smad3 and PI3-kinase in murine adriamycin nephropathy indicate distinct mechanisms of proteinuria and fibrogenesis. *Kidney Int* 82: 525–536.
- Hubchak SC, Sparks EE, Hayashida T, Schnaper HW (2009) Rac1 promotes TGF-beta-stimulated mesangial cell type I collagen expression through a PI3K/Akt-dependent mechanism. *Am J Physiol Renal Physiol* 297: F1316–F1323.
- Ghosh Choudhury G, Abboud HE (2004) Tyrosine phosphorylation-dependent PI 3 kinase/Akt signal transduction regulates TGFbeta-induced fibronectin expression in mesangial cells. *Cell Signal* 16: 31–41.
- Mahimainathan L, Das F, Venkatesan B, Choudhury GG (2006) Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. *Diabetes* 55: 2115–2125.
- Das F, Ghosh-Choudhury N, Bera A, Dey N, Abboud HE, et al. (2013) Transforming growth factor beta integrates Smad 3 to mechanistic target of rapamycin complexes to arrest deceptor abundance for glomerular mesangial cell hypertrophy. *J Biol Chem* 288: 7756–7768.
- Das F, Ghosh-Choudhury N, Mahimainathan L, Venkatesan B, Feliars D, et al. (2008) Raptor-riCTOR axis in TGFbeta-induced protein synthesis. *Cell Signal* 20: 409–423.
- Rozen-Zvi B, Hayashida T, Hubchak SC, Hanna C, Plataniias LC, et al. (2013) TGF-beta/Smad3 activates mammalian target of rapamycin complex-1 to promote collagen production by increasing HIF-1alpha expression. *Am J Physiol Renal Physiol* 305: F485–494.
- Lamouille S, Derynck R (2007) Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. *J Cell Biol* 178: 437–451.
- Howell JJ, Ricoult SJ, Ben-Sahra I, Manning BD (2013) A growing role for mTOR in promoting anabolic metabolism. *Biochem Soc Trans* 41: 906–912.
- Laplane M, Sabatini DM (2012) mTOR signaling in growth control and disease. *Cell* 149: 274–293.
- Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. *Nat Rev Mol Cell Biol* 12: 21–35.
- Foster KG, Acosta-Jaquez HA, Romeo Y, Ekim B, Soliman GA, et al. (2010) Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. *J Biol Chem* 285: 80–94.
- Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. *Science* 332: 1317–1322.
- Yu Y, Yoon SO, Pouligiannis G, Yang Q, Ma XM, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. *Science* 332: 1322–1326.
- Chen CH, Sarbasov dos D (2011) The mTOR (mammalian target of rapamycin) kinase maintains integrity of mTOR complex 2. *J Biol Chem* 286: 40386–40394.
- Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao D, et al. (2013) Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. *Nat Cell Biol* 15: 1340–1350.
- Morita M, Gravel SP, Chenard V, Sikstrom K, Zheng L, et al. (2013) mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. *Cell Metab* 18: 698–711.
- Hagiwara A, Cornu M, Cybulski N, Polak P, Betz C, et al. (2012) Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. *Cell Metab* 15: 725–738.
- Masui K, Tanaka K, Akhavan D, Babic I, Gini B, et al. (2013) mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. *Cell Metab* 18: 726–739.
- Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, et al. (2009) The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. *Biochem Biophys Res Commun* 384: 471–475.
- Nagai K, Matsubara T, Mima A, Sumi E, Kanamori H, et al. (2005) Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. *Kidney Int* 68: 552–561.
- Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, et al. (2006) Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. *J Am Soc Nephrol* 17: 1395–1404.
- Sataranatarajan K, Mariappan MM, Lee MJ, Feliars D, Choudhury GG, et al. (2007) Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. *Am J Pathol* 171: 1733–1742.
- Eid AA, Ford BM, Bhandary B, de Cassia Cavaglieri R, Block K, et al. (2013) Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury. *Diabetes* 62: 2935–2947.
- Das F, Ghosh-Choudhury N, Bera A, Kasinath BS, Choudhury GG (2013) TGFbeta-induced PI 3 kinase-dependent Mnk-1 activation is necessary for Ser-209 phosphorylation of eIF4E and mesangial cell hypertrophy. *J Cell Physiol* 228: 1617–1626.
- Thomas GV, Tran C, Mellinoff IK, Welsbie DS, Chan E, et al. (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. *Nat Med* 12: 122–127.
- Dey N, Das F, Ghosh-Choudhury N, Mandal CC, Parekh DJ, et al. (2012) microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. *PLoS One* 7: e37366.
- Dey N, Das F, Mariappan MM, Mandal CC, Ghosh-Choudhury N, et al. (2011) MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. *J Biol Chem* 286: 25586–25603.
- Das F, Ghosh-Choudhury N, Dey N, Mandal CC, Mahimainathan L, et al. (2012) Unrestrained Mammalian target of rapamycin complexes 1 and 2

- increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of akt kinase. *J Biol Chem* 287: 3808–3822.
40. Ghosh-Choudhury T, Mandal CC, Woodruff K, St Clair P, Fernandes G, et al. (2009) Fish oil targets PTEN to regulate NFκB for downregulation of anti-apoptotic genes in breast tumor growth. *Breast Cancer Res Treat* 118: 213–228.
  41. Mahaimanathan L, Ghosh-Choudhury N, Venkatesan B, Das F, Mandal CC, et al. (2009) TSC2 deficiency increases PTEN via HIF1α. *J Biol Chem* 284: 27790–27798.
  42. Dey N, Ghosh-Choudhury N, Kasinath BS, Choudhury GG (2012) TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. *PLoS One* 7: e42316.
  43. Bera A, Ghosh-Choudhury N, Dey N, Das F, Kasinath BS, et al. (2013) NFκB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation. *Cell Signal* 25: 2575–2586.
  44. Mandal CC, Ghosh-Choudhury N, Yoneda T, Choudhury GG (2011) Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. *J Biol Chem* 286: 11314–11327.
  45. Zinzalla V, Stracka D, Oppliger W, Hall MN (2011) Activation of mTORC2 by association with the ribosome. *Cell* 144: 757–768.
  46. Runyan CE, Schnaper HW, Poncelet AC (2004) The phosphatidylinositol 3-kinase/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factor-β. *J Biol Chem* 279: 2632–2639.
  47. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, et al. (2009) DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. *Cell* 137: 873–886.
  48. Sarbasov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science* 307: 1098–1101.
  49. Poncelet AC, de Caestecker MP, Schnaper HW (1999) The transforming growth factor-β/SMAD signaling pathway is present and functional in human mesangial cells. *Kidney Int* 56: 1354–1365.
  50. Basu RK, Hubchak S, Hayashida T, Runyan CE, Schumacker PT, et al. (2011) Interdependence of HIF-1α and TGF-β/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. *Am J Physiol Renal Physiol* 300: F898–905.
  51. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG, Jr (2003) TSC2 regulates VEGF through mTOR-dependent and -independent pathways. *Cancer Cell* 4: 147–158.
  52. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, et al. (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. *Mol Cell* 39: 171–183.
  53. Sarbasov DD, Ali SM, Kim DH, Guertin DA, Latek RR, et al. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. *Curr Biol* 14: 1296–1302.
  54. Lan HY (2011) Diverse roles of TGF-β/Smads in renal fibrosis and inflammation. *Int J Biol Sci* 7: 1056–1067.
  55. Inoki K, Mori H, Wang J, Suzuki T, Hong S, et al. (2011) mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. *J Clin Invest* 121: 2181–2196.
  56. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, et al. (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. *Science* 335: 1638–1643.
  57. Gangloff YG, Mueller M, Dann SG, Svoboda P, Sticker M, et al. (2004) Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. *Mol Cell Biol* 24: 9508–9516.
  58. Welsh GI, Hale LJ, Eremina V, Jeansson M, Maezawa Y, et al. (2010) Insulin signaling to the glomerular podocyte is critical for normal kidney function. *Cell Metab* 12: 329–340.
  59. Morelon E, Kreis H (2003) Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. *Transplant Proc* 35: 52S–57S.
  60. Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, et al. (2005) Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. *Nephrol Dial Transplant* 20: 2517–2523.
  61. Franz S, Regeniter A, Hopfer H, Mihatsch M, Dickenmann M (2010) Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. *Am J Kidney Dis* 55: 335–343.
  62. Torras J, Herrero-Fresneda I, Gulas O, Flaquer M, Vidal A, et al. (2009) Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage? *Nephrol Dial Transplant* 24: 3632–3640.
  63. Godel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, et al. (2011) Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. *J Clin Invest* 121: 2197–2209.
  64. Proud CG (2009) Dynamic balancing: DEPTOR tips the scales. *J Mol Cell Biol* 1: 61–63.
  65. Lieberthal W, Levine JS (2009) The role of the mammalian target of rapamycin (mTOR) in renal disease. *J Am Soc Nephrol* 20: 2493–2502.
  66. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, et al. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. *Mol Cell* 25: 903–915.
  67. Inoki K (2008) Role of TSC-mTOR pathway in diabetic nephropathy. *Diabetes Res Clin Pract* 82 Suppl 1: S59–62.
  68. Dey N, Ghosh-Choudhury N, Das F, Li X, Venkatesan B, et al. (2010) PRAS40 acts as a nodal regulator of high glucose-induced TORC1 activation in glomerular mesangial cell hypertrophy. *J Cell Physiol* 225: 27–41.
  69. Semenza GL (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. *Trends Mol Med* 8: S62–67.
  70. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, et al. (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. *Genes Dev* 18: 2893–2904.
  71. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW (2008) Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. *Genes Dev* 22: 239–251.
  72. Cam H, Easton JB, High A, Houghton PJ (2010) mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. *Mol Cell* 40: 509–520.
  73. Thompson CB (2009) Metabolic enzymes as oncogenes or tumor suppressors. *N Engl J Med* 360: 813–815.
  74. Kaelin WG, Jr. (2011) Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. *Cold Spring Harb Symp Quant Biol* 76: 335–345.
  75. Bartrons R, Caro J (2007) Hypoxia, glucose metabolism and the Warburg's effect. *J Bioenerg Biomembr* 39: 223–229.
  76. Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F (2010) Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. *Oncogene* 29: 2746–2752.
  77. Hardt M, Chantaravisoont N, Tamanoi F (2011) Activating mutations of TOR (target of rapamycin). *Genes Cells* 16: 141–151.
  78. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, et al. (2002) Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. *Mol Cell Biol* 22: 7004–7014.
  79. Toschi A, Lee E, Gadir N, Ohh M, Foster DA (2008) Differential dependence of hypoxia-inducible factors 1α and 2α on mTORC1 and mTORC2. *J Biol Chem* 283: 34495–34499.
  80. Pawlus MR, Hu CJ (2013) Enhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response. *Cell Signal* 25: 1895–1903.
  81. Kasivisvanathan V, Shalhoub J, Lim CS, Shepherd AC, Thapar A, et al. (2011) Hypoxia-inducible factor-1 in arterial disease: a putative therapeutic target. *Curr Vasc Pharmacol* 9: 333–349.
  82. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C (2002) Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-β pathways. *J Biol Chem* 277: 43799–43808.
  83. Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, et al. (2001) Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression. *J Biol Chem* 276: 38527–38535.